

Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients

SUPPLEMENTARY MATERIALS

Supplementary Table 1: Clinicopathological features of the study population


| Median age at diagnosis | 61 years (30–83) | <i>N</i> | % |
|--|--|----------|-----|
| Sex | Women | 23 | 56% |
| | Men | 18 | 44% |
| Smoking status | Former/quit | 19 | 46% |
| | Never | 22 | 54% |
| Histology | Adenocarcinoma | 39 | 95% |
| | Squamous cell carcinoma | 2 | 5% |
| UICC Stage | III | 4 | 10% |
| | IV | 37 | 90% |
| EGFR mutation | exon 19 deletion | 24 | 59% |
| | exon 20 insertion | 3 | 7% |
| | G719X | 4 | 10% |
| | L858R | 10 | 24% |
| Number of treatment lines monitored throughout the study | 1 line | 32 | 78% |
| | 2 lines | 6 | 15% |
| | 3 lines | 3 | 7% |
| Treatment ¹ | 1st line TKI treatment | 35 | 85% |
| | Gefitinib | 11 | 27% |
| | Erlotinib | 20 | 49% |
| | Afatinib | 5 | 12% |
| | Gefitinib + Olaparib | 1 | 2% |
| | 2nd line TKI treatment | 4 | 10% |
| | Osimertinib | 1 | 2% |
| | Afatinib + Cetuximab | 1 | 2% |
| | Erlotinib + Pemetrexed | 1 | 2% |
| | Gefitinib + Pemetrexed | 1 | 2% |
| | Non TKI treatment (stage III patients) | 2 | 5% |
| | Cisplatin-Vinorelbine | 1 | 5% |
| Pemetrexed | 1 | 5% | |

¹Initial treatment within the study period.

Supplementary Table 2: Progression free survival (PFS) and 95% confidence interval (CI) according to sensitizing mutation

| Tumor Mutation | median PFS (in months) | 95% CI |
|-------------------|------------------------|----------|
| deletion exon 19 | 23.9 | 8.7–58 |
| G719X | 3.13 | NA |
| L858R | 12.8 | 5.4–18.6 |
| insertion exon 20 | 2.4 | NA |
| Overall | 14.2 | 8.0–23.9 |

Supplementary Table 3: Limit of detection (LOD) and limit of quantification (LOQ) estimation for rare allele assays according to ICH guidelines. See_Supplementary_Table 3



Supplementary Figure 1: (A) and (B) Performance of EGFR sensitizing mutation assays among non-progressed patients during the study follow-up and had a partial response as their best response (as defined by RECIST criteria). Only patients with a minimum of four plasma samples extracted at different time points are presented ($N = 6$). As shown in the figure, patients experienced a decrease in EGFR-activating mutation levels. In responding patients plasma EGFR mutations levels fluctuated as much as 9076 copies/ml to undetectable levels. Only patients with a minimum of four plasma samples extracted at different time points are presented ($N = 17$).